This node covers the lab-testing and clinical-evidence layer of the healthcare technology stack: specimen collection, central laboratory processing, molecular assays, liquid biopsy, sequencing instruments, sample-prep workflows, lab automation, service contracts, and clinical data products. Aging demand matters here because older patients use more routine lab work, oncology testing, chronic-disease monitoring, transplant surveillance, and screening. The shareholder mechanism is narrower than test volume: a company has to turn a test, instrument, assay, service contract, or data product into reimbursed revenue, stable average selling price, collected cash, guideline adoption, consumable pull-through, or lower lab workflow cost.
What the stack is: clinical labs, molecular diagnostics, genomic sequencing, lab automation, sample-to-insight software, and clinical data services that turn patient samples into medical evidence.
What it does in the parent chain: it converts aging-linked care demand into requisitions, covered tests, screening volume, monitoring evidence, recurring consumables, instrument utilization, service revenue, and data products.
Main pieces: patient access sites, specimen logistics, central labs, assays, reagents, sequencing instruments, molecular workflow kits, laboratory information systems, data curation, payer billing, and physician or biopharma reporting.
Where it sits: in physician offices, hospitals, outpatient draw centers, reference labs, pathology labs, sequencing labs, customer research labs, and biopharma data workflows.
How the theme uses it: older patients create more diagnostic and monitoring events; companies get paid only when coverage, coding, collections, consumables, service attach, or data contracts convert those events into revenue and cash.
Terms used later: requisition means a submitted lab order; ASP means average selling price per test; RPR means revenue per requisition; MRD means minimal residual disease monitoring after cancer treatment; cfDNA means cell-free DNA used in many blood-based tests; consumable pull-through means reagent and kit demand created by an installed instrument base.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, confirmation triggers, invalidation checks, and chart provenance. Durable research, claim IDs, raw source registries, and sector thesis maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-18.
Current Setup
Paid evidence gateTest demand helps only when coverage, collections, and workflow economics hold.
Direct diagnostics have the clearest conversion route; broad tools names need instrument utilization, recurring consumables, service attach, or customer funding evidence before lab activity becomes shareholder cash.
Positive proofDGX, NTRA, GH, VCYT, and TEM show direct testing or clinical-data revenue.
Q2 and Q3 need volume, ASP, payer coverage, gross margin, and cash conversion moving together.
Primary constraintTools demand is still funding- and capex-sensitive.
ILMN, QGEN, A, DHR, and TMO need utilization, consumables, service, order breadth, and China/tariff control.
Demand sourceAging patients + oncology
Lab actionTest, sequence, automate
Payment routeCoverage, ASP, claims
Proof pointMargin, cash, reuse
Aging raises demand for routine lab work, oncology screening, recurrence monitoring, transplant surveillance, chronic-disease testing, genomic sequencing, pathology throughput, and hospital monitoring. That demand helps shareholders only when volume becomes paid claims, collected cash, better gross margin, or recurring consumables. The core measurements are requisitions, revenue per requisition, ASP, payer mix, denials, days sales outstanding, clinical-utility evidence, positive-predictive value, false-positive burden, guideline inclusion, instrument utilization, service attach, and operating cash flow.
The strongest current evidence is in source-backed direct diagnostics. DGX has the broadest clinical-lab conversion route, with Q1 2026 revenue growth, double-digit requisition growth, and raised guidance. NTRA, GH, VCYT, and TEM add higher-growth molecular testing, oncology monitoring, CRC screening, reimbursed genomic testing, and lab-data exposure. VCYT brings a fresh filed lane with Q1 2026 testing revenue equal to about 97% of total revenue, Decipher up 30%, Afirma up 21%, raised 2026 guidance, and positive operating cash flow. ILMN and QGEN supply sequencing and molecular workflow inputs. A, DHR, and TMO supply lab automation, diagnostic instruments, services, and broad workflow scale. The next positive proof is Q2 and Q3 evidence that test volume, payer coverage, ASP, collections, gross margin, and cash flow improve together.
The main headwind is paid-volume leakage. A company can process more tests or place more instruments while realized price, collections, or cash flow weakens. CMS CLFS/PAMA reporting in 2026 sets up 2027 payment updates, commercial payers can tighten prior authorization or coverage, molecular tests can face MolDX or local coverage limits, and broad tools names can be hit by lab capex, NIH and biotech funding, China, tariffs, and acquisition integration. VCYT adds Medicare/UnitedHealthcare concentration, PAMA reset risk, and new-test adoption risk for Prosigna and TrueMRD. TEM has a short public trading history, EXAS has no local OHLC in this workspace, and several creative tails need source lanes before promotion.
Selected-security right-rail charts use weekly bars aggregated from discovery daily_ohlc through 2026-06-18. The latest week is partial; confirmation triggers require a completed weekly close. Static setup thresholds from the prior 2026-06-11 package should be refreshed before use as current trading evidence. Fundamental claims route to the Health Care sector lane, reimbursement-dispersion theme, AI biology validation theme, funding-dependency theme, and linked security lanes.
Basket
This basket is inherited from the parent theme and hand-reranked for this node. Ranking uses source-backed diagnostics economics first, financial conversion second, and chart timing only as a secondary check. VCYT moves into the core because its fresh filed lane shows a direct genomic-testing revenue model with Q1 2026 testing revenue, Decipher/Afirma growth, raised guidance, and positive operating cash flow. Direct paid-test names come first; sequencing, molecular workflow, and broad lab-tool platforms follow because they are one step further from reimbursed patient volume. No new watch-only names were added.
National reference-lab network with the clearest route from aging test demand to paid requisitions and collected claims.
Market cap$20.7B
Next earningsNot confirmed
Latest qtr revenue$2.895B
Role in stack
Quest collects specimens from physicians, hospitals, health systems, employers, consumers, and payer channels, then processes routine, advanced, cardiometabolic, Alzheimer's blood-test, and oncology monitoring work through a national lab network.
Revenue mix
Diagnostic Information Services generated $2.832B of Q1 2026 revenue, about 98% of total revenue. Requisition volume rose 10.9%, while revenue per requisition fell 1.3%, so mix quality and collections remain the gate.
Proof burden
Requisition growth needs stable revenue per requisition, payer mix, denials, DSO, margin, and free cash flow so acquisition-aided volume becomes collected revenue.
Specialty molecular diagnostics platform with high-growth cfDNA testing across women's health, oncology, and organ health.
Market cap$27.7B
Next earningsNot confirmed
Latest qtr revenue$696.6M
Role in stack
Natera sells and processes specialty molecular tests for women's health, oncology MRD, organ health, and biopharma customers. The economic route is payer coverage, ASP, test volume, lab scale, and cash generation.
Revenue mix
Q1 2026 revenue was mostly product/test revenue in one reportable segment. The company processed about 1.014M tests, including 258,900 oncology tests, so oncology mix and collections matter more than a segment split.
Proof burden
Oncology and organ-health growth need payer coverage, ASP, collections, lab-scale margin, and cash flow to keep test volume from becoming only working-capital load.
Liquid-biopsy and screening platform with oncology tests, Shield CRC screening, and biopharma data exposure.
Market cap$12.7B
Next earningsNot confirmed
Latest qtr revenue$301.7M
Role in stack
Guardant turns blood samples into oncology treatment selection, recurrence monitoring, CRC screening, companion diagnostics, and biopharma data. The conversion gate is Shield payer mix and ASP, follow-up capacity, Reveal reimbursement, and cash burn.
Revenue mix
Q1 2026 revenue was split across Oncology at $205.0M, Biopharma and Data at $53.0M, Screening at $41.6M, and Licensing/Other at $2.1M.
Proof burden
Shield, oncology, and Reveal need reimbursement, follow-up capacity, clinical utility, gross margin, and cash-burn control to prove blood-test volume converts into durable economics.
Profitable genomic diagnostics platform with Decipher and Afirma turning specialty testing demand into paid revenue and cash flow.
Market cap$4.3B
Next earningsNot confirmed
Latest qtr revenue$139.1M
Role in stack
Veracyte sells genomic tests to clinicians and health systems for prostate, thyroid, bladder, breast, and MRD use cases. The conversion route is specialist adoption, payer coverage, claim collection, lab scale, and cash flow from Decipher and Afirma.
Revenue mix
Q1 2026 testing revenue was $135.1M, about 97% of total revenue. Decipher revenue was $86.5M, up 30%, and Afirma revenue was $46.4M, up 21%; product and biopharma/other were small.
Proof burden
Q2/Q3 testing revenue needs to stay on or above the raised guide, while PAMA, Medicare, UnitedHealthcare, commercial collections, adjusted EBITDA quality, and Prosigna/TrueMRD uptake do not dilute cash conversion.
Diagnostics-funded clinical data and AI workflow route with explicit lab-data monetization.
Market cap$9.0B
Next earningsNot confirmed
Latest qtr revenue$348.1M
Role in stack
Tempus receives oncology, hereditary, liquid biopsy, and MRD samples from providers, then sells diagnostics, data, modeling, trial matching, and workflow tools to providers, health systems, and biopharma customers.
Revenue mix
Q1 2026 Diagnostics revenue was $261.1M, about 75% of total revenue, and Data and Applications revenue was $87.0M, about 25%.
Proof burden
Diagnostics growth needs to fund data, workflow, and model revenue without hiding collection risk, acquisition integration cost, or cash-flow leakage.
Sequencing infrastructure supplier whose installed base can support clinical, research, and diagnostic lab workflows.
Market cap$21.5B
Next earningsNot confirmed
Latest qtr revenue$1.091B
Role in stack
Illumina sells sequencing instruments, consumables, services, and related applications to clinical, research, pharma, hospital, government, and diagnostic-lab customers. The node route is installed-base utilization and recurring consumables.
Revenue mix
Q1 2026 revenue included $917M of product revenue and $174M of service and other revenue. Consumables pull-through and NovaSeq X utilization are the useful stack checks.
Proof burden
Sequencing demand needs NovaSeq X utilization, clinical pull-through, consumable volume, service attach, and customer funding to offset instrument-cycle and China risk.
Molecular workflow and sample-to-insight supplier with recurring consumables but a guide-reset setup.
Market cap$6.8B
Next earningsNot confirmed
Latest qtr revenue$492M
Role in stack
QIAGEN sells sample technologies, diagnostic solutions, PCR and nucleic-acid amplification, digital PCR, clinical bioinformatics, and NGS support. Conversion comes from consumables, placements, launches, and customer budget resilience.
Revenue mix
FY2025 consumables and related revenue were about 90% of sales. Q1 2026 net sales were spread across Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, Genomics/NGS, and other lines.
Proof burden
Sample-to-insight demand needs QuantiFERON, QIAcuity, consumables, placements, launches, and customer budgets to recover after guidance pressure.
Clinical lab technology and service platform with Life Sciences and Diagnostics plus CrossLab workflow exposure.
Market cap$32.7B
Next earningsNot confirmed
Latest qtr revenue$1.835B
Role in stack
Agilent sells clinical lab technology, pathology and genomics tools, automation, instruments, software, and CrossLab services. The node route is lab throughput, service attach, and replacement-cycle durability.
Revenue mix
Q2 FY2026 revenue included Life Sciences and Diagnostics Markets at $732M, Agilent CrossLab at $759M, and Applied Markets at $344M.
Proof burden
Lab throughput needs to show up in Life Sciences and Diagnostics, CrossLab service attach, order breadth, margin, and instrument replacement demand.
Diversified diagnostics and life-science tools platform with scale but muted current core growth.
Market cap$121.1B
Next earningsNot confirmed
Latest qtr revenue$6.0B
Role in stack
Danaher routes through diagnostics, life-science tools, bioprocessing, lab automation, molecular diagnostics, pathology, Radiometer, Cepheid, Beckman Coulter, Leica, and possible monitoring exposure through Masimo.
Revenue mix
Danaher reports Biotechnology, Life Sciences, and Diagnostics. The platform has recurring diagnostics and tools exposure, but it is diversified enough that diagnostics demand must show up in segment recovery and core growth.
Proof burden
Diagnostics and life-science tools need segment core growth, recurring revenue, order recovery, margin, and acquisition discipline to matter inside a diversified platform.
Broad lab infrastructure and specialty diagnostics platform with scale but lower node purity than direct diagnostics.
Market cap$172.8B
Next earningsNot confirmed
Latest qtr revenue$11.01B
Role in stack
Thermo Fisher supplies lab products, specialty diagnostics, analytical instruments, consumables, clinical research services, Clario endpoint data, and laboratory productivity tools for clinical and research labs.
Revenue mix
Q1 2026 revenue was broad across lab products, specialty diagnostics, life-science tools, clinical research, services, and Clario. The useful check is organic acceleration, not just acquisition-supported revenue growth.
Proof burden
Broad lab exposure needs organic growth, order breadth, specialty diagnostics demand, service pull-through, and Clario integration to offset lower node purity.
Market caps for the pre-existing nine cards retain the prior read-only discovery instruments.market_cap values queried on 2026-06-13. VCYT uses the 2026-06-18 local close times weighted shares from its filed lane, about $4.3B; the stored instrument market-cap field was lower at $3.2B. Company IR event pages and Nasdaq earnings pages checked on 2026-06-13 did not provide confirmed next earnings dates for the original nine card names, and VCYT's source lane did not include a confirmed next earnings date, so every card uses Not confirmed. Latest-quarter revenue uses each company's latest official Q1 2026 release, except Agilent, which had already reported Q2 FY2026.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
01Node thesis
Volume becomes paid evidence
What confirms
Testing volume, screening volume, MRD volume, instrument utilization, consumables, service attach, and data revenue rise with stable or better ASP, coverage, gross margin, collections, and cash flow. VCYT adds a core-test check: Decipher and Afirma growth need to stay tied to cash conversion.
What weakens or invalidates
Volume rises while RPR, ASP, payer mix, denial rates, AR, DSO, false-positive burden, or free cash flow worsens.
Watch next
Q2/Q3 requisitions
ASP/RPR
OCF and FCF
02Payment and collections
Claims get collected
What confirms
CMS, Medicare contractors, and commercial payers keep coverage intact while companies collect claims on time and keep bad debt controlled. For VCYT, Medicare, UnitedHealthcare, PAMA, and commercial collections need to stay stable for Decipher, Afirma, and Decipher Bladder.
Tests show decision-changing evidence, guideline inclusion, positive-predictive value, follow-up capacity, and lower clinical friction. VCYT confirms by preserving Decipher and Afirma evidence/coverage and by showing Prosigna or TrueMRD adoption with reimbursement.
What weakens or invalidates
False positives, weak evidence, colonoscopy or specialist bottlenecks, limited guideline adoption, or narrow labels slow use.
Watch next
FDA Shield updates
NCCN/ASCO/ACS/USPSTF
MRD evidence
VCYT new-test uptake
04Lab data and AI
Data contracts pay
What confirms
TEM and GH convert diagnostics scale into paid data, modeling, trial, biopharma, and workflow revenue with visible margin and renewals.
What weakens or invalidates
Diagnostics revenue subsidizes bundled AI/data claims while Data and Applications or Biopharma/Data fails to improve cash conversion.
Watch next
TEM data revenue
GH biopharma data
OCF and renewals
05Tools and customer funding
Utilization supports pull-through
What confirms
ILMN, QGEN, A, DHR, and TMO show instrument utilization, consumable pull-through, services, order breadth, and clinical lab workflow demand.
What weakens or invalidates
Lab capex freezes, NIH or biotech funding weakens, China or tariff headwinds rise, placements fail to create consumables, or acquisition integration absorbs cash.
Watch next
NovaSeq X utilization
QuantiFERON/QIAcuity
A CrossLab
TMO organic growth
06Stale condition
Refresh before trading use
What confirms
Discovery daily_ohlc remains current, right-rail API charts resolve, source lanes still cover the latest company evidence, and no new earnings, filings, payer decisions, or guidance updates arrive before this page is refreshed.
What weakens or invalidates
A new trading session, earnings release, 10-Q, payer policy, FDA update, reimbursement decision, guidance change, M&A filing, or major customer funding update arrives before the node is refreshed.
Watch next
API as_of date
Source-lane refresh
Q2 releases
Setup threshold refresh
07Watch and source gaps
Do not promote thin lanes
What confirms
LH, IRTC, CDNA, MYGN, NEO, and PSNL get source lanes and current official result packs.
What weakens or invalidates
Watch names are treated as researched core without local lanes, or EXAS is charted before local OHLC and public-status routing are reconciled.
Market caps use read-only discovery and filed source-lane checks. The original nine card values retain the prior 2026-06-13 instruments.market_cap package: DGX $20.7B, NTRA $27.7B, GH $12.7B, TEM $9.0B, ILMN $21.5B, QGEN $6.8B, A $32.7B, DHR $121.1B, and TMO $172.8B. VCYT uses local 2026-06-18 close times weighted shares from the VCYT lane, about $4.3B; read-only discovery status also showed stored instrument.market_cap of $3.2B.
Next-earnings search was bounded to official company IR event pages where accessible and Nasdaq earnings pages for DGX, NTRA, GH, TEM, ILMN, QGEN, A, DHR, and TMO, checked on 2026-06-13. Nasdaq returned "Data is currently not available" for the visible earnings-date field, company event pages did not provide a confirmed next earnings date, and the VCYT lane did not include a confirmed next earnings date, so the cards use Not confirmed.
Latest-quarter revenue sources: DGX Quest Q1 2026 release for the quarter ended March 31, 2026; NTRA Natera Q1 2026 release; GH Guardant Health Q1 2026 release; VCYT Veracyte Q1 2026 release and latest filed research/profile output; TEM Tempus AI Q1 2026 release; ILMN Illumina Q1 FY2026 release; QGEN QIAGEN Q1 2026 release; A Agilent Q2 FY2026 release; DHR Danaher Q1 2026 release; TMO Thermo Fisher Q1 2026 release.
Discovery And Chart Provenance
Read-only discovery coverage checks used discovery status DGX --json, discovery lineage-status --ticker DGX --dataset daily_ohlc --limit 10 --json, /home/nick/projects/portfolio-manager/discovery/.venv/bin/python -m discovery.cli status VCYT --json, /home/nick/projects/portfolio-manager/discovery/.venv/bin/python -m discovery.cli lineage-status --ticker VCYT --dataset daily_ohlc --limit 10 --json, and read-only DuckDB Python queries against ../discovery/data/discovery.duckdb. Core names had local rows through 2026-06-18 after adding VCYT.
Weekly bars group daily rows by calendar week: first open, maximum high, minimum low, final close, and summed volume.
The right-rail chart package uses 20-week and 100-week EMAs computed from weekly closes before clipping the visible chart window, plus a volume subgraph. The latest bar is partial because 2026-06-18 was not a completed trading week.
The right-rail chart contract is /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. Node HTML does not embed OHLC arrays.
Representative API validation on 2026-06-13 attempted /api/securities/DGX/chart?frequency=weekly&window=3y&as_of=latest. The local API process reported startup, but sibling curl calls to 127.0.0.1:8765 could not connect in this sandbox. API chart/security unit tests passed; live HTTP chart rendering remains deferred to an accessible report API process.
All core names except TEM had more than three years of local daily rows. TEM has daily OHLC from 2024-06-14 through 2026-06-18, so its selected-security chart cannot show a full three-year public trading window. VCYT has daily OHLC from 2021-05-12 through 2026-06-18.
Static setup thresholds retained in metadata were authored from the 2026-06-11 package. If the live API returns newer chart data, refresh those thresholds before using them as current trading evidence.
Known Gaps
LH is the cleanest lab-network peer to DGX, but it needs a local security lane before promotion from watch.
EXAS is relevant to CRC screening, but local discovery has no OHLC rows and public-status routing needs reconciliation after Abbott's announced acquisition work.
IRTC is the best monitoring tail, but it needs a filed local lane and official-source bundle before core inclusion.
CDNA, MYGN, NEO, and PSNL are molecular diagnostics or pathology watch names. They need source lanes, reimbursement checks, cash-flow evidence, and setup refreshes before ranking.
TXG and PACB have local lanes and chart data. Their primary evidence route is genomics tools and AI-biology data, with paid diagnostics volume still unproven.
ABT, DXCM, RMD, and Masimo belong mainly in medtech, chronic monitoring, sleep, diabetes, or acute-care device routes unless diagnostics revenue becomes the main mechanism.
VCYT is now core, not watch-only. Remaining VCYT gaps are call-transcript coverage, peer multiple context, and adoption/reimbursement evidence for Prosigna and TrueMRD.